Bristol-myers Squibb

This study looks at the long-term safety of nivolumab and other cancer drugs in people with different types of cancer. It is for patients who have already taken part in a Bristol-Myers Squibb trial and may continue treatment. The goal is to track side effects and see how well the…

This study tests a drug called luspatercept for people with alpha-thalassemia, a blood disorder that causes anemia. The goal is to see if it can reduce the need for blood transfusions and raise hemoglobin levels. About 189 adults and teens will take part. The drug is given as a s…

This study tests a new drug, BMS-986458, in about 308 adults with non-Hodgkin lymphoma that returned or didn't respond to prior treatments. The drug works by breaking down a protein that helps cancer cells grow. Researchers will check safety, side effects, and whether the drug sh…

This study tests whether a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy works better than the current standard (pembrolizumab plus chemotherapy) for people with advanced non-squamous non-small cell lung cancer whose tumors have PD-L1 lev…

This study compares two daily pills, ozanimod and fingolimod, in children and teens aged 10-17 with relapsing-remitting multiple sclerosis (RRMS). The goal is to see which drug better prevents relapses and reduces brain lesions. Participants will be randomly assigned to one of th…

This study looks at how KarXT affects bladder function and overall safety in 60 adults with schizophrenia. Participants will stop their current antipsychotics and take KarXT for 12 months. The goal is to see if the drug causes any urinary problems or other side effects.

This study compares a new drug called pumitamig combined with chemotherapy against a standard treatment (bevacizumab plus chemo) for people with advanced colorectal cancer that cannot be removed by surgery. About 990 participants will receive either treatment to see which works b…

This study tests whether a newer pill (deucravacitinib) is safer for the heart than an older injected drug (ustekinumab) in people with moderate-to-severe plaque psoriasis. About 3,040 adults who also have heart risk factors like smoking, high blood pressure, or diabetes will tak…

This study looks at how well ozanimod works compared to azathioprine for people with steroid-dependent ulcerative colitis. Researchers will track 150 adults in Japan to see which treatment helps patients achieve remission without needing steroids. The goal is to find a safer, mor…

This study tests whether adding a new drug (navlimetostat) to standard immunotherapy and chemotherapy can help people with advanced lung cancer that has a specific missing gene (MTAP deletion). About 590 participants will receive either the new combo or a placebo plus standard tr…

This study tests a new drug, BMS-986340, alone or with other cancer treatments (nivolumab or docetaxel) in people with advanced solid tumors that have worsened after standard therapy. The goal is to find safe doses and understand side effects. About 949 adults with various cancer…

This study tests an experimental drug called BMS-986490, given alone or with bevacizumab, for people with advanced solid tumors that have stopped responding to standard treatments. The tumors must have a specific marker called CEACAM5. The main goals are to check safety and find …

This study tests an oral medication called deucravacitinib in teenagers aged 12 to 17 with moderate to severe plaque psoriasis. The goal is to see if the drug can clear or nearly clear skin and reduce itching compared to a placebo. About 366 participants will take the drug or a d…

This study tests an experimental drug called KarXT in 166 teenagers (ages 13-17) with schizophrenia. The goal is to see if KarXT safely reduces symptoms like hallucinations and social withdrawal better than a placebo. Participants will receive either the drug or a dummy pill for …

This phase 3 study compares a new drug called pumitamig to the current standard drug durvalumab in people with stage III lung cancer that cannot be removed by surgery. Participants must have completed chemotherapy and radiation without their cancer getting worse. The main goal is…

This early-stage study is testing an experimental drug called BMS-986326 in 44 adults with different forms of lupus (discoid, subacute cutaneous, or systemic). The main goal is to see if the drug is safe and how the body processes it when given as multiple doses by IV or injectio…

This study tests the long-term safety of an experimental drug called KarXT for treating mania or mixed episodes in people with Bipolar-I disorder. About 450 adults who either completed a previous KarXT study or are new participants will take the drug openly for up to one year. Th…

This study follows 350 adults in France with moderate-to-severe plaque psoriasis who are starting a new medication called deucravacitinib. Researchers will track how well the drug controls skin symptoms and improves quality of life over time in everyday medical practice. The goal…

This early-stage trial tests an experimental drug called MRTX1719 in adults with advanced solid tumors that have a missing MTAP gene. The study aims to find a safe dose and see if the drug can shrink tumors or slow their growth. About 336 participants with cancers like mesothelio…

This study tests whether adding the experimental drug BMS-986504 to standard chemotherapy helps people with a specific type of advanced pancreatic cancer live longer or slow tumor growth. It is for patients whose tumors have a missing MTAP gene. About 470 participants will receiv…

This early-stage study tests a new drug called BMS-986500 in people with advanced solid tumors or breast cancer that has stopped responding to standard treatments. The goal is to see if the drug is safe and how the body processes it. About 234 adults will take part, receiving the…

This study tests a new experimental drug combination (BMS-986507) in about 416 adults with advanced lung or breast cancer that has spread. The main goals are to find safe doses and see if the drugs can shrink tumors. Participants must have tried other treatments and be in relativ…

This study is tracking 1500 adults with schizophrenia who are starting a new medication called KarXT (xanomeline and trospium chloride). Researchers want to see how well it works in everyday life, what side effects occur, and how doctors adjust the dose. The goal is to understand…

This early-stage study tests a new drug called BMS-986517 in adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goal is to check the drug's safety and side effects. About 315 participants will receive the drug, and researchers will also l…

This phase 3 trial tests whether a new drug combination (BMS-986489 plus chemotherapy) works better than the current standard treatment (atezolizumab plus chemotherapy) for people with extensive-stage small cell lung cancer. About 530 participants will receive one of the two trea…

This study follows 200 people in Japan who are taking mavacamten for obstructive hypertrophic cardiomyopathy, a condition where the heart muscle thickens and blocks blood flow. Researchers want to see how well the drug works and what side effects occur in everyday use. The goal i…

This study tests an experimental drug called BMS-986525, given alone or with an immunotherapy drug (nivolumab), in about 240 people whose small cell lung cancer has returned or stopped responding to standard chemotherapy. The main goals are to check safety and side effects, and t…

This study tests a new drug, BMS-986506, for people with advanced clear cell renal cell carcinoma (a type of kidney cancer) that has not responded to other treatments. The main goal is to check if the drug is safe and tolerable. About 125 adults who have already tried at least tw…

This study tests an oral medication called deucravacitinib in children aged 4 to 17 with moderate to severe plaque psoriasis. The goal is to find the right dose and see if it safely clears skin and reduces symptoms. Participants will be followed for up to 5 years to monitor long-…

This study tests a new drug called pumitamig, alone or with other medicines (ipilimumab or cabozantinib), in people with advanced kidney cancer that has spread. The goal is to see if these combinations are safe and can shrink tumors or slow the disease. About 234 adults with clea…

This study is testing how well the drug mavacamten works for Chinese adults with a type of heart disease called obstructive hypertrophic cardiomyopathy. About 500 people will take the drug as part of their normal care, and doctors will measure changes in heart function and sympto…

This study follows 200 Italian adults with moderate to severe psoriasis who are already taking the oral medication deucravacitinib. Researchers will track how well the drug controls skin symptoms, its safety, and how it affects quality of life over time. The goal is to see how th…

This study tests a new drug called BMS-986482, given alone or with other treatments, for people with advanced solid tumors that have not responded to standard therapies. The goal is to check safety and how well the drug works. About 413 adults with various advanced cancers will t…

This program provides access to iberdomide for people who qualify. It is not a cure and is meant to help manage the disease. Participants must meet specific criteria to join.

This early-stage study tests a new drug, BMS-986504, in up to 32 Japanese and Chinese adults with advanced solid tumors that have a specific genetic change (MTAP deletion). The main goals are to check the drug's safety and how the body processes it. Participants must have tried o…

This early-stage study tests an experimental drug called BMS-986460 in men with metastatic castration-resistant prostate cancer, a type of prostate cancer that has spread and stopped responding to standard hormone therapy. The main goals are to check the drug's safety and find th…

This early-stage study tests a new drug called BMS-986463 in people with advanced ovarian, uterine, or lung cancers that have spread and cannot be removed by surgery. The main goals are to check the drug's safety and find the best dose. About 240 participants will receive the dru…

This study is testing a new experimental drug called BMS-986523, given alone or with other cancer medicines, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the right dose. About 252 adult…

This study tests a new drug, izalontamab brengitecan, against standard chemotherapy for people with advanced bladder cancer that got worse after immunotherapy. About 470 adults will be randomly assigned to receive either the new drug or chemo. The goal is to see if the new drug c…

This study compares two treatment combinations for people with advanced or metastatic stomach, gastroesophageal junction, or esophageal cancer who have not had prior treatment. One group receives the experimental drug pumitamig plus chemotherapy, while the other receives the stan…

This study tests a new drug, BMS-986504, in people with advanced or spreading non-small cell lung cancer that has a specific genetic change (MTAP deletion) and has stopped responding to earlier treatments. About 130 participants will receive the drug alone to see if it shrinks tu…

This early-stage study tests a new medicine called BMS-986470 in healthy volunteers and people with sickle cell disease. The main goal is to check safety and how the body processes the drug. About 184 participants will take either the drug or a placebo to gather initial data on d…

This study tests a new medicine called izalontamab brengitecan for people with advanced triple-negative breast cancer or ER-low breast cancer that cannot be treated with immunotherapy. The drug targets specific proteins on cancer cells to deliver a chemotherapy-like payload direc…

This study tests a daily medication called deucravacitinib in 60 children aged 5 to 17 who have active juvenile psoriatic arthritis and haven't responded well to other treatments. The goal is to see if the drug can prevent arthritis flares and is safe for long-term use. Participa…

This study compares a new drug called pumitamig to the standard treatment pembrolizumab (Keytruda) for people with advanced non-small cell lung cancer whose tumors have high levels of a protein called PD-L1. The goal is to see if pumitamig works better at stopping cancer growth a…

This study provides ongoing treatment with deucravacitinib for people with lupus (SLE or DLE/SCLE) who finished a previous study. It aims to keep managing the disease long-term. Only 35 participants who are likely to benefit and meet eligibility criteria will be enrolled.

This study tests an oral medication called ozanimod in 120 children aged 12-17 with moderate-to-severe ulcerative colitis who haven't improved with standard treatments. The goal is to see if the drug can safely bring the disease into remission (no symptoms) and keep it there. Par…

This study tests an experimental drug, BMS-986435/MYK-224, in 208 adults with a type of heart failure where the heart pumps normally but is too stiff. The goal is to check the drug's safety and how the body processes it. Participants will receive either the drug or a placebo, and…

This early study tests a new drug called BMS-986497 in people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) whose cancer has returned or not responded to other treatments. The drug is given alone or together with standard medicines (azacitidine and venetocla…

This study is testing a new drug, CC-92480, combined with other therapies for people whose multiple myeloma has come back or stopped responding to treatment. The goal is to find safe doses and see if the combination can shrink tumors. About 260 participants will take part in this…

This study tests a new drug called pumitamig, either alone or with another drug (ipilimumab), in people with advanced liver cancer that cannot be removed by surgery. About 129 participants will receive the treatment to see if it is safe and helps shrink tumors. The goal is to con…

This program offers expanded access to mezigdomide, an experimental drug, for people with serious conditions who cannot join a clinical trial. It is designed to provide treatment when no other options are available. Participants must meet specific eligibility criteria set by the …

This study tests whether a new drug, iberdomide, works better than the current standard lenalidomide as maintenance therapy after a stem cell transplant in people newly diagnosed with multiple myeloma. About 1,200 participants will receive either drug to see which one delays canc…

This study tests a new drug, izalontamab brengitecan, against standard chemotherapy for people with a specific type of lung cancer (EGFR-mutated non-small cell lung cancer) that has gotten worse after taking targeted pills called EGFR tyrosine kinase inhibitors. About 596 adults …

This study looks at how well a drug called mavacamten works for adults in Japan who have a heart condition called obstructive hypertrophic cardiomyopathy (HOCM). In HOCM, the heart muscle is too thick and blocks blood flow, causing symptoms like chest pain and shortness of breath…

This study is testing a drug called luspatercept in adults with a severe blood disorder called beta-thalassemia who need regular blood transfusions. The goal is to see if the drug can reduce how many transfusions they need and improve their hemoglobin levels. About 200 people in …

This study looks at whether switching teen kidney transplant patients (ages 12-17) from standard anti-rejection drugs to a newer medication called belatacept can help preserve kidney function and improve how consistently they take their medicine. About 102 participants will be ra…

This study tests whether a combination of two drugs, KarXT and KarX-EC, can safely reduce agitation in people with Alzheimer's disease. About 352 adults with Alzheimer's-related agitation will receive either the drug or a placebo. The main goal is to see if agitation scores impro…

This study tests whether adding the drug KarXT to standard mood stabilizers (lithium, valproate, or lamotrigine) can better control manic episodes in people with bipolar I disorder. About 424 adults hospitalized for mania will receive either KarXT or a placebo for 5 weeks. The ma…

This study tests whether a combination of two drugs, KarXT and KarX-EC, can safely reduce agitation in adults with Alzheimer's disease. About 352 participants will receive either the drug or a placebo, and researchers will measure changes in agitation levels after 14 weeks. The g…

This early-stage study is testing a long-acting injectable form of KarXT for people with schizophrenia. The main goals are to check safety and how the drug moves through the body. About 48 participants will receive a single injection, and researchers will monitor side effects and…

This study tests whether the experimental drug KarXT can reduce symptoms of mania in people with Bipolar I disorder who are currently hospitalized for a manic or mixed episode. About 274 adults will receive either KarXT or a placebo for 3 weeks while staying in the hospital. The …

This study tests a new drug combination, KarXT + KarX-EC, to see if it can improve memory and thinking in people with mild to moderate Alzheimer's disease. About 586 participants will receive either the drug or a placebo. The goal is to measure changes in cognitive function and d…

This study tests if the drug KarXT can safely reduce manic symptoms in people with Bipolar-I disorder who are currently hospitalized for a manic episode. About 274 adults will receive either KarXT or a placebo, and researchers will measure changes in mania severity using a standa…

This study tests a drug called KarXT in about 250 Japanese adults with schizophrenia who are currently having severe symptoms (psychosis). The goal is to see if KarXT reduces symptoms like hallucinations and delusions better than a placebo over 5 weeks, and then to check its safe…

This study tests the long-term safety of an experimental drug combination (KarXT) for treating agitation in people with Alzheimer's disease. About 600 participants who completed earlier studies will take the drug and be monitored for side effects. The goal is to see if the drug r…

This study tests whether a new combination drug, KarXT + KarX-EC, can safely reduce hallucinations and delusions in people with Alzheimer's disease. About 325 adults aged 55 to 90 with Alzheimer's and psychosis will receive either the drug or a placebo. The goal is to see if the …

This study tests whether a new drug combination, KarXT + KarX-EC, can improve memory and thinking in people with mild to moderate Alzheimer's disease. About 586 participants will receive either the drug or a placebo, and researchers will measure changes in thinking skills and dai…

This study is a registry that will follow about 1,600 adults with obstructive hypertrophic cardiomyopathy (a type of heart muscle disease) in the US and Europe. Researchers will observe how patients are treated in everyday practice, including those taking the drug mavacamten, and…

This study monitors the health of women who took the heart medication mavacamten during pregnancy or while breastfeeding, along with their babies. Researchers will track pregnancy complications, birth outcomes, and infant development through the first year of life. The goal is to…

This study follows about 1,200 pregnant women with multiple sclerosis who have taken the drug ozanimod (ZEPOSIA). Researchers will track the health of mothers, fetuses, and babies to better understand any risks. The goal is to help patients and doctors make informed decisions abo…

This study is for healthy adults to see how different tablet versions of the drug BMS-986435 are absorbed by the body. It also checks if eating food changes how the drug works. About 140 participants will take part to help researchers understand the best tablet form.

This study tests whether a new wet-granulation tablet of navlimetostat works the same as the current dry-granulation tablet in healthy adult women. About 64 participants will receive both tablet forms at different times to compare how the drug is absorbed and processed. The goal …

This study is for people with active lupus (including lupus kidney disease) who haven't gotten better with steroids and at least two immunosuppressants. Researchers will watch how well current standard treatments work over time, focusing on remission rates and safety. About 223 p…

This study looks at how satisfied adults with schizophrenia are with a new medication called xanomeline and trospium chloride (X/T). Researchers will ask 300 participants about their treatment preferences and reasons for any changes. The goal is to gather real-world information, …

This early-stage study tests an experimental drug called BMS-986521 in healthy adults to see if it is safe and how the body processes it. About 106 participants will receive either the drug or a placebo. The study does not aim to treat any disease; it simply gathers important saf…

This study looks at tumor samples from 50 people who developed a second cancer after receiving a BMS-made CAR-T cell therapy. Researchers will test whether the original treatment's genes are present in the new tumor. The goal is to understand if the therapy played a role, not to …

This study looks at 720 elderly Italian patients with non-valvular atrial fibrillation (an irregular heartbeat) to understand why some are prescribed blood thinners and others are not. Researchers will follow participants for one year to see how many stick with their treatment an…

This study aims to understand the daily experiences, symptoms, and quality of life of 50 people in Japan with low-risk myelodysplastic syndrome (MDS) or unexplained anemia. Participants will fill out questionnaires and may be interviewed about their symptoms, treatment satisfacti…

This study interviews 55 people — patients with early-stage lung cancer and their doctors — to learn what matters most when choosing treatment. Researchers want to understand preferences and priorities to help guide future care decisions. No new drugs or treatments are being test…

This study is tracking 362 adults with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle thickens and blocks blood flow) who are taking the drug mavacamten in regular U.S. clinics. Researchers want to see how the drug affects blood pressure, heart functi…

This early-stage study is testing new versions of two experimental drugs, KarX and KarT, in 72 healthy adults. The goal is to measure how the body absorbs and processes these new formulas compared to the original versions, and to see if food changes how they work. This research d…

This study looks at how a new drug (BMS-986504) moves through and leaves the body in people with advanced solid tumors that have a missing MTAP gene. Eight participants will receive a radioactive-labeled version of the drug so researchers can measure its levels in blood, urine, a…

This study tests whether the experimental drug BMS-986278 changes the heart's electrical activity in 32 healthy adults aged 18 to 55. Participants receive the drug, a placebo, and a positive control in random order. The goal is to check for heart rhythm risks, not to treat any di…